Aspirin and a PoTent P2Y12 Inhibitor Versus Aspirin and Clopidogrel in Patients Undergoing PCI for Complex Lesion

Summary

This study is a prospective, open label, two-arm, randomized multicenter trial to evaluate the efficacy and safety of aspirin plus prasugrel as compared with aspirin plus clopidogrel in patients undergoing elective percutaneous coronary intervention with drug eluting stents for complex coronary lesions.

Conditions

• Coronary Artery Disease

Interventions

DRUG

Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin

Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion 1. Prasugrel plus Aspirin arm 2. Clopidogrel plus Aspirin arm

Sponsors & Collaborators

• Inje University Ilsan Paik Hospital

  collaborator OTHER

• Seoul St. Mary's Hospital

  collaborator OTHER

• Mediplex Sejong Hospital

  collaborator UNKNOWN

• Chonnam National University Hospital

  collaborator OTHER

• Sejong General Hospital

  collaborator OTHER

• Wonkwang University Hospital

  collaborator OTHER

• Gachon University Gil Medical Center

  collaborator OTHER

• Keimyung University Dongsan Medical Center

  collaborator OTHER

• Chungbuk National University Hospital

  collaborator OTHER

• Yeungnam University Hospital

  collaborator OTHER

• Chungnam National University Hospital

  collaborator OTHER

• Wonju Severance Christian Hospital

  collaborator OTHER

• Konkuk University Chungju Hospital

  collaborator UNKNOWN

• Chung-Ang University Hosptial, Chung-Ang University College of Medicine

  collaborator OTHER

• Dankook University

  collaborator OTHER

• Incheon St.Mary's Hospital

  collaborator OTHER

• Gyeongsang National University Hospital

  collaborator OTHER

• Soonchunhyang University Hospital

  collaborator OTHER

• Ewha Womans University Seoul Hospital

  collaborator OTHER

• Samsung Medical Center

  lead OTHER

Principal Investigators

• Joo-Yong Hahn, MD, PhD · Samsung Medical Center

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

19 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-01-13

Primary Completion

2027-06-30

Completion

2028-12-31

Countries

• South Korea

Study Locations